TNSN00198A1 - COMPOSES NOUVEAUX INHIBITEURS DE cGMP PDE, PROCEDE POUR LEUR PREPARATION ET FORMULATIONS LES CONTENANT. - Google Patents

COMPOSES NOUVEAUX INHIBITEURS DE cGMP PDE, PROCEDE POUR LEUR PREPARATION ET FORMULATIONS LES CONTENANT.

Info

Publication number
TNSN00198A1
TNSN00198A1 TNTNSN00198A TNSN00198A TNSN00198A1 TN SN00198 A1 TNSN00198 A1 TN SN00198A1 TN TNSN00198 A TNTNSN00198 A TN TNSN00198A TN SN00198 A TNSN00198 A TN SN00198A TN SN00198 A1 TNSN00198 A1 TN SN00198A1
Authority
TN
Tunisia
Prior art keywords
preparation
compounds
formulations containing
cgmp pde
new inhibitors
Prior art date
Application number
TNTNSN00198A
Other languages
English (en)
Inventor
Moira Norfor Allerton Charlotte
Gordon Barber Christopher
Nigel Maw Graham
James Rawson David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924041.8A external-priority patent/GB9924041D0/en
Priority claimed from GB0018660A external-priority patent/GB0018660D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN00198A1 publication Critical patent/TNSN00198A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELLE R1, R2, R3, R4 ET X REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT DES FORMULATIONS LES CONTENANT, AINSI QU'UN PROCEDE POUR LEUR PREPARATION. APPLICATION : UTILISATION D'UN TEL COMPOSE OU D'UNE TELLE FORMULATION DANS LE TRAITEMENT OU LA PREVENTION D'UN ETAT PATHOLOGIQUE POUR LEQUEL UNE INHIBITION DE LA cGMP PDE EST DESIREE.
TNTNSN00198A 1999-10-11 2000-10-10 COMPOSES NOUVEAUX INHIBITEURS DE cGMP PDE, PROCEDE POUR LEUR PREPARATION ET FORMULATIONS LES CONTENANT. TNSN00198A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924041.8A GB9924041D0 (en) 1999-10-11 1999-10-11 Pharmaceutically active compounds
GB0018660A GB0018660D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
TNSN00198A1 true TNSN00198A1 (fr) 2002-05-30

Family

ID=26244758

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00198A TNSN00198A1 (fr) 1999-10-11 2000-10-10 COMPOSES NOUVEAUX INHIBITEURS DE cGMP PDE, PROCEDE POUR LEUR PREPARATION ET FORMULATIONS LES CONTENANT.

Country Status (34)

Country Link
US (1) US6756373B1 (fr)
EP (1) EP1222190A1 (fr)
JP (1) JP2003511452A (fr)
KR (1) KR20020038941A (fr)
CN (1) CN1378547A (fr)
AP (1) AP2002002455A0 (fr)
AR (1) AR022665A1 (fr)
AU (1) AU7547900A (fr)
BG (1) BG106568A (fr)
BR (1) BR0014695A (fr)
CA (1) CA2387353A1 (fr)
CO (1) CO5261539A1 (fr)
CZ (1) CZ20021151A3 (fr)
DZ (1) DZ3218A1 (fr)
EA (1) EA200200240A1 (fr)
EE (1) EE200200192A (fr)
GT (1) GT200000168A (fr)
HK (1) HK1049834A1 (fr)
HU (1) HUP0203438A3 (fr)
IL (1) IL149025A0 (fr)
IS (1) IS6288A (fr)
MA (1) MA26824A1 (fr)
NO (1) NO20021695L (fr)
NZ (1) NZ517324A (fr)
OA (1) OA12058A (fr)
PA (1) PA8504401A1 (fr)
PE (1) PE20010736A1 (fr)
PL (1) PL357522A1 (fr)
SK (1) SK4562002A3 (fr)
SV (1) SV2002000192A (fr)
TN (1) TNSN00198A1 (fr)
TR (1) TR200200954T2 (fr)
UY (1) UY26383A1 (fr)
WO (1) WO2001027112A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6271228B1 (en) * 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
US6809200B2 (en) 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
EP1176142A1 (fr) * 2000-07-28 2002-01-30 Pfizer Inc. Procédé pour la préparation de pyrazoles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
WO2003020702A2 (fr) 2001-08-31 2003-03-13 The Rockefeller University Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
PL374198A1 (en) * 2002-05-23 2005-10-03 Pfizer Inc. Novel combination
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
JP4208512B2 (ja) 2002-07-23 2009-01-14 株式会社クラレ ５−（２’−ピリジル）−２−ピリドン誘導体の製造方法
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
RU2331438C2 (ru) 2002-12-13 2008-08-20 Уорнер-Ламберт Компани Ллс Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
RS20050810A (en) 2003-04-29 2007-08-03 Pfizer Inc., 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
DE602005017135D1 (de) * 2004-03-05 2009-11-26 Nycomed Gmbh Neue verwendung von pde5-hemmern
WO2005097799A1 (fr) 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3[4,3-d]pyrimidines
ES2313626T3 (es) 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
AU2006245416B2 (en) 2005-05-12 2012-02-23 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006133261A2 (fr) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Composes organiques
EP1919287A4 (fr) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc Composés organiques pour traiter un signald'activité réduit du récepteur de la dopamine
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
RU2008120332A (ru) * 2005-12-20 2010-01-27 Пфайзер Продактс Инк. (Us) Фармацевтическая композиция для лечения luts, содержащая ингибитор pde5 и мускариновый антагонист
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2008044767A1 (fr) * 2006-10-13 2008-04-17 Takeda Pharmaceutical Company Limited Dérivé d'amine aromatique et utilisation de celui-ci
ES2411604T3 (es) * 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
ES2310144B1 (es) * 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
US20100210668A1 (en) * 2007-10-02 2010-08-19 Dong-A Pharm. Co., Ltd. Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms
EP2240028B1 (fr) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Dérivés de Pyrazolopyrimidine-4,6-dione et leur utilisation pharmaceutique
DK2240490T3 (da) 2007-12-06 2013-12-16 Takeda Pharmaceutical Organiske forbindelser
CN102238872A (zh) * 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
AU2009322905A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
ES2638912T3 (es) 2008-12-06 2017-10-24 Intra-Cellular Therapies, Inc. Compuestos orgánicos
SG171776A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
CA2740385A1 (fr) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Composes organiques
GEP20146046B (en) 2008-12-06 2014-02-25 Intracellular Therapies Inc Organic compounds
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
EP2400970A4 (fr) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc Inhibiteur de pde 1 pour troubles ophtalmiques
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
WO2011153138A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2013067309A1 (fr) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Procédés et compositions pour l'administration orale de composés agonistes d'un récepteur de la mélanocortine
WO2013109738A1 (fr) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
AU2014234990B2 (en) 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
ES2776353T3 (es) 2013-07-17 2020-07-30 Univ Columbia Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
WO2015196186A1 (fr) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Composés organiques
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2857567T3 (es) 2014-09-17 2021-09-29 Intra Cellular Therapies Inc Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
RU2702732C1 (ru) 2014-12-06 2019-10-10 Интра-Селлулар Терапиз, Инк. Органические соединения
EP3436083A4 (fr) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (fr) 2017-09-08 2019-03-14 Incyte Corporation Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
SI3755703T1 (sl) 2018-02-20 2022-11-30 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamidni derivati in sorodne spojine kot zaviralci HPK1 za zravljenje raka
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
ES2224130T3 (es) 1994-08-09 2005-03-01 Eisai Co., Ltd. Compuesto de piridazina condensada.
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
HUP9801394A3 (en) 1995-03-10 2000-07-28 Sanofi Pharmaceuticals Inc New 6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5798375A (en) 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
TR199902646T2 (xx) 1997-04-25 2000-05-22 Pfizer Inc. Seks�el bozuklu�un tedavisi i�in pirazolopirimidinonlar.
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
JP3721077B2 (ja) * 1998-04-20 2005-11-30 ファイザー・インク 性的不全を治療するためのピラゾロピリミジノンｃＧＭＰＰＤＥ５阻害剤
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
ES2205945T3 (es) 1998-10-23 2004-05-01 Pfizer Inc. Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales.
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6809200B2 (en) * 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
US6407259B1 (en) * 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US20020165237A1 (en) * 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20020173502A1 (en) * 2001-03-09 2002-11-21 Allerton Charlotte Moira Norfor Pharmaceutically active compounds
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
WO2003012095A1 (fr) 2001-07-28 2003-02-13 Midwest Research Institute Exoglucanase thermo-tolerante d'acidothermus cellulolyticus

Also Published As

Publication number Publication date
AR022665A1 (es) 2002-09-04
KR20020038941A (ko) 2002-05-24
PE20010736A1 (es) 2001-07-19
PA8504401A1 (es) 2002-04-25
HK1049834A1 (zh) 2003-05-30
CN1378547A (zh) 2002-11-06
IS6288A (is) 2002-02-26
CA2387353A1 (fr) 2001-04-19
AP2002002455A0 (en) 2002-06-30
PL357522A1 (en) 2004-07-26
CZ20021151A3 (cs) 2003-03-12
EP1222190A1 (fr) 2002-07-17
CO5261539A1 (es) 2003-03-31
OA12058A (en) 2006-05-03
NO20021695L (no) 2002-06-07
HUP0203438A3 (en) 2003-05-28
BG106568A (bg) 2002-12-29
EA200200240A1 (ru) 2002-10-31
NZ517324A (en) 2003-09-26
IL149025A0 (en) 2002-11-10
EE200200192A (et) 2003-06-16
GT200000168A (es) 2002-04-03
UY26383A1 (es) 2001-05-31
MA26824A1 (fr) 2004-12-20
NO20021695D0 (no) 2002-04-10
JP2003511452A (ja) 2003-03-25
BR0014695A (pt) 2002-06-18
HUP0203438A2 (hu) 2003-01-28
SK4562002A3 (en) 2003-04-01
DZ3218A1 (fr) 2001-04-19
TR200200954T2 (tr) 2002-09-23
WO2001027112A1 (fr) 2001-04-19
AU7547900A (en) 2001-04-23
SV2002000192A (es) 2002-07-16
US6756373B1 (en) 2004-06-29

Similar Documents

Publication Publication Date Title
TNSN00198A1 (fr) COMPOSES NOUVEAUX INHIBITEURS DE cGMP PDE, PROCEDE POUR LEUR PREPARATION ET FORMULATIONS LES CONTENANT.
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01091A1 (fr) Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98140A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN00228A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TNSN98053A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant.
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00191A1 (fr) Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98045A1 (fr) Derives de nicotinamide nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99198A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN02022A1 (fr) Triazolopyridines anti-inflammatoires nouvelles, et compositions les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97122A1 (fr) Inhibiteurs des metalloproteinases de matrice a base de phosphinates
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99147A1 (fr) Procede d'emulsification
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant